口服药物-话题@MedSci

#口服药物#

33篇内容 | 1631人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1910400, encodeId=9d4e191040055, content=<a href='/topic/show?id=d7cd38234fc' target=_blank style='color:#2F92EE;'>#口服药物#</a>, objectTitle=重磅！辉瑞新冠病毒口服药物Paxlovid，国内获附条件批准, objectType=article, longId=295532, objectId=6d76295532fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d76295532fc, replyNumber=0, likeNumber=108, createdTime=2022-04-23, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d76295532fc, moduleTitle=重磅！辉瑞新冠病毒口服药物Paxlovid，国内获附条件批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d76295532fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910404, encodeId=524b1910404ae, content=<a href='/topic/show?id=d7cd38234fc' target=_blank style='color:#2F92EE;'>#口服药物#</a>, objectTitle=EMI：张文宏团队公布新冠口服药物VV116治疗效果, objectType=article, longId=727336, objectId=7cd8e27336f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7cd8e27336f0, replyNumber=0, likeNumber=71, createdTime=2022-08-13, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7cd8e27336f0, moduleTitle=EMI：张文宏团队公布新冠口服药物VV116治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7cd8e27336f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910396, encodeId=3e34191039622, content=<a href='/topic/show?id=d7cd38234fc' target=_blank style='color:#2F92EE;'>#口服药物#</a>, objectTitle=英国批准默沙东新冠口服药物molnupiravir，开创新冠治疗的新时代！, objectType=article, longId=219813, objectId=f9052198134a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9052198134a, replyNumber=0, likeNumber=93, createdTime=2022-10-16, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9052198134a, moduleTitle=英国批准默沙东新冠口服药物molnupiravir，开创新冠治疗的新时代！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9052198134a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910399, encodeId=4d581910399d9, content=<a href='/topic/show?id=d7cd38234fc' target=_blank style='color:#2F92EE;'>#口服药物#</a>, objectTitle=Sci Adv：这种廉价的口服药物，让癌症脑转移放疗效果倍增！, objectType=article, longId=220430, objectId=8b2e2204302c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b2e2204302c, replyNumber=0, likeNumber=113, createdTime=2022-08-25, rootId=0, userName=JR19860219, userId=20b5274, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b2e2204302c, moduleTitle=Sci Adv：这种廉价的口服药物，让癌症脑转移放疗效果倍增！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b2e2204302c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910403, encodeId=188019104033e, content=<a href='/topic/show?id=d7cd38234fc' target=_blank style='color:#2F92EE;'>#口服药物#</a>, objectTitle=先声制药新冠病毒3CL口服药物SIM0417首例患者入组, objectType=article, longId=724228, objectId=a17ae24228f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a17ae24228f4, replyNumber=0, likeNumber=85, createdTime=2022-04-29, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a17ae24228f4, moduleTitle=先声制药新冠病毒3CL口服药物SIM0417首例患者入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a17ae24228f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910402, encodeId=fc8819104029e, content=<a href='/topic/show?id=d7cd38234fc' target=_blank style='color:#2F92EE;'>#口服药物#</a>, objectTitle=新冠口服药物Paxlovid，中国售价达2300元一盒！, objectType=article, longId=301777, objectId=0702301e77cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0702301e77cf, replyNumber=0, likeNumber=86, createdTime=2023-01-18, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0702301e77cf, moduleTitle=新冠口服药物Paxlovid，中国售价达2300元一盒！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0702301e77cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910405, encodeId=4f1a1910405b3, content=<a href='/topic/show?id=d7cd38234fc' target=_blank style='color:#2F92EE;'>#口服药物#</a>, objectTitle=DOM：三联疗法口服药物控制不佳的2型糖尿病患者加用替格列汀的有效性和安全性, objectType=article, longId=727370, objectId=0f88e2737005, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f88e2737005, replyNumber=0, likeNumber=81, createdTime=2022-08-16, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f88e2737005, moduleTitle=DOM：三联疗法口服药物控制不佳的2型糖尿病患者加用替格列汀的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f88e2737005)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910394, encodeId=df9a191039421, content=<a href='/topic/show?id=d7cd38234fc' target=_blank style='color:#2F92EE;'>#口服药物#</a>, objectTitle=DOM：基础胰岛素联合口服药物治疗2型糖尿病患者，将基础胰岛素改为甘精胰岛素300U/mL的疗效和安全性观察, objectType=article, longId=218151, objectId=419321815137, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=419321815137, replyNumber=0, likeNumber=84, createdTime=2021-11-06, rootId=0, userName=JR19860219, userId=20b5274, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=419321815137, moduleTitle=DOM：基础胰岛素联合口服药物治疗2型糖尿病患者，将基础胰岛素改为甘精胰岛素300U/mL的疗效和安全性观察, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=419321815137)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910401, encodeId=f41c1910401d3, content=<a href='/topic/show?id=d7cd38234fc' target=_blank style='color:#2F92EE;'>#口服药物#</a>, objectTitle=2022年2月13日简报：国内批准辉瑞新冠特效口服药物Paxlovid上市，对奥密克戎变异有效；奥密克戎可能同样会导致儿童多系统炎症综合症, objectType=article, longId=295553, objectId=7b0d29555340, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b0d29555340, replyNumber=0, likeNumber=89, createdTime=2022-08-29, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b0d29555340, moduleTitle=2022年2月13日简报：国内批准辉瑞新冠特效口服药物Paxlovid上市，对奥密克戎变异有效；奥密克戎可能同样会导致儿童多系统炎症综合症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b0d29555340)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910398, encodeId=27e2191039822, content=<a href='/topic/show?id=d7cd38234fc' target=_blank style='color:#2F92EE;'>#口服药物#</a>, objectTitle=2021年11月6日简报：辉瑞新冠口服药物Paxlovid降低住院或死亡率89%！有望终结新冠；中国内地31省份新冠疫苗接种超23亿剂次；, objectType=article, longId=219883, objectId=7bca2198830a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bca2198830a, replyNumber=0, likeNumber=83, createdTime=2021-12-19, rootId=0, userName=JR19860219, userId=20b5274, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bca2198830a, moduleTitle=2021年11月6日简报：辉瑞新冠口服药物Paxlovid降低住院或死亡率89%！有望终结新冠；中国内地31省份新冠疫苗接种超23亿剂次；, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bca2198830a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910397, encodeId=5b18191039e7a, content=<a href='/topic/show?id=d7cd38234fc' target=_blank style='color:#2F92EE;'>#口服药物#</a>, objectTitle=终结新冠！辉瑞新冠口服药物Paxlovid降低住院或死亡率89%！即使是出现症状5天内，仍然极其有效！, objectType=article, longId=219868, objectId=145b21986877, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=145b21986877, replyNumber=0, likeNumber=86, createdTime=2022-10-03, rootId=0, userName=JR19860219, userId=20b5274, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=145b21986877, moduleTitle=终结新冠！辉瑞新冠口服药物Paxlovid降低住院或死亡率89%！即使是出现症状5天内，仍然极其有效！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=145b21986877)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910395, encodeId=a4ff19103956a, content=<a href='/topic/show?id=d7cd38234fc' target=_blank style='color:#2F92EE;'>#口服药物#</a>, objectTitle=2021年10月26日简报：湖北、浙江、海南等地启动3-11岁人群新冠病毒疫苗接种；欧洲药品管理局开始滚动审查默沙东新冠口服药物, objectType=article, longId=219276, objectId=11432192e670, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=11432192e670, replyNumber=0, likeNumber=84, createdTime=2022-02-10, rootId=0, userName=JR19860219, userId=20b5274, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=11432192e670, moduleTitle=2021年10月26日简报：湖北、浙江、海南等地启动3-11岁人群新冠病毒疫苗接种；欧洲药品管理局开始滚动审查默沙东新冠口服药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=11432192e670)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910391, encodeId=202119103911e, content=<a href='/topic/show?id=d7cd38234fc' target=_blank style='color:#2F92EE;'>#口服药物#</a>, objectTitle=FDA批准血液癌口服药物——低甲基化制剂Inqovi, objectType=article, longId=197254, objectId=a8b119e2542e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8b119e2542e, replyNumber=0, likeNumber=81, createdTime=2020-08-18, rootId=0, userName=JR19860219, userId=20b5274, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8b119e2542e, moduleTitle=FDA批准血液癌口服药物——低甲基化制剂Inqovi, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a8b119e2542e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910393, encodeId=3f5219103938c, content=<a href='/topic/show?id=d7cd38234fc' target=_blank style='color:#2F92EE;'>#口服药物#</a>, objectTitle=Nat Microbiol：口服药物MK-4482 / EIDD-2801或可阻止SARS-CoV-2传播, objectType=article, longId=204233, objectId=da092042334e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da092042334e, replyNumber=0, likeNumber=108, createdTime=2020-12-23, rootId=0, userName=JR19860219, userId=20b5274, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da092042334e, moduleTitle=Nat Microbiol：口服药物MK-4482 / EIDD-2801或可阻止SARS-CoV-2传播, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da092042334e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910390, encodeId=954b1910390ce, content=<a href='/topic/show?id=d7cd38234fc' target=_blank style='color:#2F92EE;'>#口服药物#</a>, objectTitle=第一个也是**的GLP-1激动剂口服药物Rybelsus，再次获认可, objectType=article, longId=196867, objectId=4cbc19686e58, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cbc19686e58, replyNumber=0, likeNumber=85, createdTime=2021-02-08, rootId=0, userName=JR19860219, userId=20b5274, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cbc19686e58, moduleTitle=第一个也是**的GLP-1激动剂口服药物Rybelsus，再次获认可, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cbc19686e58)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910389, encodeId=a3ce19103891e, content=<a href='/topic/show?id=d7cd38234fc' target=_blank style='color:#2F92EE;'>#口服药物#</a>, objectTitle=FDA批准治疗复发或难治性大B细胞淋巴瘤患者的口服药物：核出口抑制剂XPOVIO, objectType=article, longId=196393, objectId=d7b919639342, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7b919639342, replyNumber=0, likeNumber=97, createdTime=2021-02-09, rootId=0, userName=JR19860219, userId=20b5274, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7b919639342, moduleTitle=FDA批准治疗复发或难治性大B细胞淋巴瘤患者的口服药物：核出口抑制剂XPOVIO, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7b919639342)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910392, encodeId=151e1910392d1, content=<a href='/topic/show?id=d7cd38234fc' target=_blank style='color:#2F92EE;'>#口服药物#</a>, objectTitle=全球改善结肠镜检查结果的口服药物Methylene Blue MMX，在欧洲获批, objectType=article, longId=199856, objectId=7f37199856fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f37199856fa, replyNumber=0, likeNumber=96, createdTime=2021-02-25, rootId=0, userName=JR19860219, userId=20b5274, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f37199856fa, moduleTitle=全球改善结肠镜检查结果的口服药物Methylene Blue MMX，在欧洲获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f37199856fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910386, encodeId=88351910386a6, content=<a href='/topic/show?id=d7cd38234fc' target=_blank style='color:#2F92EE;'>#口服药物#</a>, objectTitle=Lancet：口服药物治疗重度妊高症的效果和安全性, objectType=article, longId=176767, objectId=b7d71e6767f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7d71e6767f6, replyNumber=0, likeNumber=95, createdTime=2020-02-15, rootId=0, userName=JR19860219, userId=20b5274, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7d71e6767f6, moduleTitle=Lancet：口服药物治疗重度妊高症的效果和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7d71e6767f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910387, encodeId=c185191038e54, content=<a href='/topic/show?id=d7cd38234fc' target=_blank style='color:#2F92EE;'>#口服药物#</a>, objectTitle=Sci Rep：【世界阿尔茨海默病日】口服药物，或破阿尔茨海默症治疗僵局, objectType=article, longId=179810, objectId=7a7e1e9810fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a7e1e9810fe, replyNumber=0, likeNumber=84, createdTime=2020-09-04, rootId=0, userName=JR19860219, userId=20b5274, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a7e1e9810fe, moduleTitle=Sci Rep：【世界阿尔茨海默病日】口服药物，或破阿尔茨海默症治疗僵局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a7e1e9810fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1910388, encodeId=0b0d19103882b, content=<a href='/topic/show?id=d7cd38234fc' target=_blank style='color:#2F92EE;'>#口服药物#</a>, objectTitle=Sci Rep：口服药物，或破阿尔茨海默症治疗僵局, objectType=article, longId=180020, objectId=c41518002082, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c41518002082, replyNumber=0, likeNumber=81, createdTime=2020-07-27, rootId=0, userName=JR19860219, userId=20b5274, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c41518002082, moduleTitle=Sci Rep：口服药物，或破阿尔茨海默症治疗僵局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c41518002082)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

口服药物

2020-05-29

智慧医人 (审核中...)

前往app查看评论内容

#口服药物#

重磅！辉瑞新冠病毒口服药物Paxlovid，国内获附条件批准

2022-04-23

智慧医人 (审核中...)

前往app查看评论内容

#口服药物#

EMI：张文宏团队公布新冠口服药物VV116治疗效果

2022-08-13

智者为医08 (审核中...)

前往app查看评论内容

#口服药物#

英国批准默沙东新冠口服药物molnupiravir，开创新冠治疗的新时代！

2022-10-16

JR19860219 (审核中...)

前往app查看评论内容

#口服药物#

Sci Adv：这种廉价的口服药物，让癌症脑转移放疗效果倍增！

2022-08-25

智慧医人 (审核中...)

前往app查看评论内容

#口服药物#

先声制药新冠病毒3CL口服药物SIM0417首例患者入组

2022-04-29

智慧医人 (审核中...)

前往app查看评论内容

#口服药物#

新冠口服药物Paxlovid，中国售价达2300元一盒！

2023-01-18

智慧医人 (审核中...)

前往app查看评论内容

#口服药物#

DOM：三联疗法口服药物控制不佳的2型糖尿病患者加用替格列汀的有效性和安全性

2022-08-16

JR19860219 (审核中...)

前往app查看评论内容

#口服药物#

DOM：基础胰岛素联合口服药物治疗2型糖尿病患者，将基础胰岛素改为甘精胰岛素300U/mL的疗效和安全性观察

2021-11-06

智慧医人 (审核中...)

前往app查看评论内容

#口服药物#

2022年2月13日简报：国内批准辉瑞新冠特效口服药物Paxlovid上市，对奥密克戎变异有效；奥密克戎可能同样会导致儿童多系统炎症综合症

2022-08-29

JR19860219 (审核中...)

前往app查看评论内容

#口服药物#

2021年11月6日简报：辉瑞新冠口服药物Paxlovid降低住院或死亡率89%！有望终结新冠；中国内地31省份新冠疫苗接种超23亿剂次；

2021-12-19

JR19860219 (审核中...)

前往app查看评论内容

#口服药物#

终结新冠！辉瑞新冠口服药物Paxlovid降低住院或死亡率89%！即使是出现症状5天内，仍然极其有效！

2022-10-03

JR19860219 (审核中...)

前往app查看评论内容

#口服药物#

2021年10月26日简报：湖北、浙江、海南等地启动3-11岁人群新冠病毒疫苗接种；欧洲药品管理局开始滚动审查默沙东新冠口服药物

2022-02-10

JR19860219 (审核中...)

前往app查看评论内容

#口服药物#

FDA批准血液癌口服药物——低甲基化制剂Inqovi

2020-08-18

JR19860219 (审核中...)

前往app查看评论内容

#口服药物#

Nat Microbiol：口服药物MK-4482 / EIDD-2801或可阻止SARS-CoV-2传播

2020-12-23

JR19860219 (审核中...)

前往app查看评论内容

#口服药物#

第一个也是**的GLP-1激动剂口服药物Rybelsus，再次获认可

2021-02-08

JR19860219 (审核中...)

前往app查看评论内容

#口服药物#

FDA批准治疗复发或难治性大B细胞淋巴瘤患者的口服药物：核出口抑制剂XPOVIO

2021-02-09

JR19860219 (审核中...)

前往app查看评论内容

#口服药物#

全球改善结肠镜检查结果的口服药物Methylene Blue MMX，在欧洲获批

2021-02-25

JR19860219 (审核中...)

前往app查看评论内容

#口服药物#

Lancet：口服药物治疗重度妊高症的效果和安全性

2020-02-15

JR19860219 (审核中...)

前往app查看评论内容

#口服药物#

Sci Rep：【世界阿尔茨海默病日】口服药物，或破阿尔茨海默症治疗僵局

2020-09-04

JR19860219 (审核中...)

前往app查看评论内容

#口服药物#

Sci Rep：口服药物，或破阿尔茨海默症治疗僵局

2020-07-27

科室
- - 订阅+
  - 更多科室
工具
服务